At Novo Holdings, we aspire to a set of values that define the way we work. Our values underpin the Novo Holdings culture of high performance with high responsibility and long-term thinking.
We are a holding and investment company
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation.
Established in 1999, Novo Holdings is the holding company of the Novo Group and manages the Foundation's investment assets.
In addition to being the major shareholder in the Novo Group companies, Novo Holdings invests the wealth of the Foundation in two key categories: 1. Life Science Investments, which includes investing in life science companies at all stages of development; and 2. Financial Investments, which manages a diversified portfolio of equity and fixed income securities.
Working out of Copenhagen, San Francisco and Boston, Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
The purpose of the investments of Novo Holdings is both to grow the assets of the Foundation and to deliver a return that the Foundation can distribute for scientific, social and humanitarian purposes to improve the health and welfare of people.
We bring more than capital to life science companies in all stages of development Kasim Kutay, CEO, Novo Holdings
How we do business
- We strive to do the right thing in the right way.
- We maintain our integrity.
- We shun complacency.
- We refer to and reinforce our values.
- We strive for high performance.
- We value team effort.
- We value collegiality.
- We give and receive feedback to improve our performance.
- We sustain long-term relationships based on mutual trust and respect.
- We are agile and aspire to be visionary.
- We uphold full discretion and confidentiality.
- We apply the lessons learned from our successes and failures.
- We uphold our Charter.
- We leverage our life science expertise as a Group to make better investment decisions.
Board of Directors
The Board of Directors comprises eight members each with a long and proven track record in investments or the life sciences.
The Novo Advisory Group is an expert panel that supports Novo Holdings in analysing the opportunities and risks associated with its larger investments.
The leadership team of Novo Holdings comprises the CEO and the heads of the six departments.
People & Organisation
Working closely with the rest of the organisation, we recruit, train and develop high-calibre international professionals, who aspire to deliver high performance with high responsibility.
Finance & Operations
Finance & Operations encompasses accounting, finance, legal and compliance as well as IT and facilities management. Our team strives to support the rest of the organisation with world-class systems, processes and procedures.
Acesion Pharma Commences Phase 1 Study in Atrial Fibrillation, developing potential first-in-class treatments with unique efficacy and safety profile.
IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer.
Novo Holdings launches an impact fund commissioned by the Novo Nordisk Foundation with a total budget of USD 165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance.
Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation
Forendo Pharma nominates world class scientific advisory board and elects Professor Linda Giudice as the Chairperson
Vantia Therapeutics announces Positive Results from its Phase III EQUINOC®
Investments and transactions
€ 5.1 bn
currently invested in the life science sector.
life science investments since 1999.
The Novo Nordisk Foundation
The Novo Nordisk Foundation
Striving to improve the health and welfare of people
The Novo Nordisk Foundation awards grants for research, humanitarian and social purposes. The history of the Foundation dates back to 1922, when Professor and Nobel Laureate August Krogh and his wife, Marie, took a trip to North America and succeeded in acquiring the necessary knowledge and permission to manufacture insulin in Scandinavia. In return, August Krogh promised that profit from the sale of insulin would be returned to society as support for scientific and humanitarian purposes.
The production of insulin marked the beginning of the development of world-class diabetes medicine and a subsequent Danish business and export venture. It also led to the establishment of several foundations that, many years later, merged into today’s Novo Nordisk Foundation. Since 2010, the Foundation has awarded grants totalling more than DKK 15 billion.
Novo Holdings A/S
Tuborg Havnevej 19
+45 3527 6500
Novo Ventures (US) Inc.*
200 Clarendon Street, Floor 45
Boston, MA 02142
Novo Ventures (US) Inc.*
1700 Owens Street, Suite 540
San Francisco, CA 94158
+1 (415) 552-6686
*Novo Ventures (US) Inc. is a separate legal entity that provides certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying, analysing and negotiating various investment opportunities among life science and biotech companies in the US as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts.